Pfizer’s Tukysa added to maintenance therapy significantly delayed disease progression in patients with HER2-positive ...
Pfizer said on Tuesday it entered into an exclusive licensing agreement with YaoPharma, a subsidiary of China's Shanghai ...
China approves 19 innovative drugs for commercial health insurance, opening new market opportunities for global and local ...
Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. Keep ...
Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, ...
Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read ...
Pfizer Inc ($PFE) announced an update on their ongoing clinical study. Pfizer Inc. has launched a Phase 1 clinical study titled A Phase 1, ...
Zacks.com on MSN
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Pfizer (PFE) settling at $25.78, representing a +1.78% change from its previous close.
Pharmaceutical Technology on MSN
Pfizer plans job cuts in Switzerland to reduce expenses
Pfizer is set to cut several jobs in Switzerland as part of a multi-year effort to lower expenses, as reported by Bloomberg.
With $6 billion left in firepower, Pfizer is planning transactions in the hundreds of millions to the low-billions range, ...
Fosun Pharmaceutical is a spinoff from Fosun International, which is chaired by China billionaire chairman Guo Guangchang; ...
Pfizer Inc. is cutting hundreds of jobs in Switzerland as part of a multi-year program to reduce costs, according to people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback